company background image
NRIX

Nurix Therapeutics NasdaqGM:NRIX Stock Report

Last Price

US$11.86

Market Cap

US$559.2m

7D

-8.8%

1Y

-60.5%

Updated

25 Nov, 2022

Data

Company Financials +
NRIX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NRIX Stock Overview

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.

Nurix Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nurix Therapeutics
Historical stock prices
Current Share PriceUS$11.86
52 Week HighUS$32.18
52 Week LowUS$7.52
Beta1.69
1 Month Change-1.74%
3 Month Change-23.14%
1 Year Change-60.55%
3 Year Changen/a
5 Year Changen/a
Change since IPO-37.61%

Recent News & Updates

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Recent updates

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Jul 24
We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Apr 15
Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%

Feb 21
Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 18
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent Results

Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More Optimistic

Jan 31
Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More Optimistic

Shareholder Returns

NRIXUS BiotechsUS Market
7D-8.8%0.4%1.3%
1Y-60.5%-14.4%-18.5%

Return vs Industry: NRIX underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: NRIX underperformed the US Market which returned -20.2% over the past year.

Price Volatility

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement9.5%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: NRIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: NRIX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009242Arthur Sandshttps://www.nurixtx.com

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.

Nurix Therapeutics, Inc. Fundamentals Summary

How do Nurix Therapeutics's earnings and revenue compare to its market cap?
NRIX fundamental statistics
Market CapUS$559.17m
Earnings (TTM)-US$171.34m
Revenue (TTM)US$39.24m

14.3x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NRIX income statement (TTM)
RevenueUS$39.24m
Cost of RevenueUS$174.92m
Gross Profit-US$135.68m
Other ExpensesUS$35.66m
Earnings-US$171.34m

Last Reported Earnings

Aug 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.63
Gross Margin-345.77%
Net Profit Margin-436.66%
Debt/Equity Ratio0%

How did NRIX perform over the long term?

See historical performance and comparison